PALI Insider Trading

Insider Ownership Percentage: 2.24%
Insider Buying (Last 12 Months): $34,791.30
Insider Selling (Last 12 Months): $192.00

Palisade Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Palisade Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palisade Bio Share Price & Price History

Current Price: $4.12
Price Change: Price Decrease of -0.26 (-5.94%)
As of 04/12/2024 01:00 AM ET

This chart shows the closing price history over time for PALI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Palisade Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2024Donald Allen WilliamsDirectorBuy666$9.00$5,994.002,000View SEC Filing Icon  
9/27/2023Donald Allen WilliamsDirectorBuy1,333$8.10$10,797.301,333View SEC Filing Icon  
9/27/2023John David FinleyCEOBuy1,000$8.10$8,100.002,892View SEC Filing Icon  
9/14/2023Robert J. TrenschelDirectorSell20$9.60$192.00View SEC Filing Icon  
9/13/2023John David FinleyCEOBuy1,000$9.90$9,900.001,892View SEC Filing Icon  
8/23/2022John David FinleyCFOBuy490$2.40$1,176.008,616View SEC Filing Icon  
8/16/2022John David FinleyCFOBuy6,666$3.75$24,997.508,126View SEC Filing Icon  
8/16/2022Thomas HallamCEOBuy2,666$3.75$9,997.503,839View SEC Filing Icon  
3/29/2022Michael John DawsonInsiderBuy1,000$17.10$17,100.00View SEC Filing Icon  
3/28/2022Thomas HallamCEOBuy666$17.70$11,788.20View SEC Filing Icon  
3/24/2022John David FinleyCFOBuy500$16.35$8,175.00View SEC Filing Icon  
9/21/2021John David FinleyCFOBuy133$36.60$4,867.80View SEC Filing Icon  
9/21/2021Thomas HallamCEOBuy400$37.35$14,940.00View SEC Filing Icon  
9/9/2021Robert J TrenschelDirectorBuy226$43.35$9,797.10116View SEC Filing Icon  
9/7/2021Robert J TrenschelDirectorBuy180$41.70$7,506.00View SEC Filing Icon  
8/31/2021Robert J. TrenschelDirectorBuy116$41.25$4,785.00116View SEC Filing Icon  
8/27/2021John David FinleyCFOBuy666$39.75$26,473.50View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Palisade Bio (NASDAQ:PALI)

11.79% of Palisade Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PALI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Palisade Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/26/2024Virtu Financial LLC51,928$31K0.0%N/A0.560%Search for SEC Filing on Google Icon
12/18/2023Vanguard Group Inc.68,054$40K0.0%+91.3%0.738%Search for SEC Filing on Google Icon
8/14/2023State Street Corp22,463$38K0.0%N/A0.327%Search for SEC Filing on Google Icon
8/11/2023Geode Capital Management LLC42,247$72K0.0%N/A0.631%Search for SEC Filing on Google Icon
2/15/2023Virtu Financial LLC20,461$0.11M0.0%-81.3%4.650%Search for SEC Filing on Google Icon
2/14/2023Two Sigma Investments LP10,396$54K0.0%-87.1%2.363%Search for SEC Filing on Google Icon
11/14/2022Renaissance Technologies LLC512,070$51K0.0%+1,396.0%2.340%Search for SEC Filing on Google Icon
11/14/2022Altium Capital Management LP5,643,007$0.56M0.2%N/A25.791%Search for SEC Filing on Google Icon
10/27/2022Sargent Investment Group LLC670,000$76K0.0%+179.2%3.062%Search for SEC Filing on Google Icon
7/26/2022Sargent Investment Group LLC240,000$98K0.0%+84.6%1.097%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.271,604$0.29M0.0%+11.5%1.490%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP333,954$0.43M0.1%N/A2.460%Search for SEC Filing on Google Icon
11/12/2021Sargent Investment Group LLC105,000$0.28M0.1%N/A0.812%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.28,841$76K0.0%+16.7%0.223%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC18,200$74K0.0%N/A0.160%Search for SEC Filing on Google Icon
8/16/2021State Street Corp28,210$0.12M0.0%N/A0.978%Search for SEC Filing on Google Icon
8/16/2021Sabby Management LLC52,500$0.21M0.0%N/A1.821%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC145,300$0.59M0.0%N/A5.040%Search for SEC Filing on Google Icon
8/13/2021Altium Capital Management LP1,824,894$7.43M1.7%N/A63.298%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC24,675$100K0.0%N/A0.856%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.237,811$0.97M0.0%N/A8.249%Search for SEC Filing on Google Icon
8/12/2021Private Advisor Group LLC21,051$86K0.0%N/A0.730%Search for SEC Filing on Google Icon
8/6/2021HighTower Advisors LLC16,666$68K0.0%N/A0.578%Search for SEC Filing on Google Icon
7/31/2021Strategic Wealth Designers53,129$0.22M0.1%N/A1.845%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
Read More on Palisade Bio

Today's Range

Now: $4.12
Low: $3.82
High: $4.57

50 Day Range

MA: $5.95
Low: $4.07
High: $7.65

52 Week Range

Now: $4.12
Low: $3.82
High: $36.60


63,504 shs

Average Volume

63,881 shs

Market Capitalization

$3.51 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Palisade Bio?

Palisade Bio's top insider investors include:
  1. John David Finley (CFO)
  2. Thomas Hallam (CEO)
  3. John David Finley (CEO)
  4. Donald Allen Williams (Director)
  5. Robert J Trenschel (Director)
Learn More about top insider investors at Palisade Bio.